Evidence map›Paper›PMID 29335927›Full record

ReviewMolecular diagnosis & therapy2018

miRNAs as Potential Treatment Targets and Treatment Options in Cancer.

Nina Petrovic, Sercan Ergun

Abstract readReview
PubMed Publisher
In one paragraph

Review in Molecular diagnosis & therapy, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Review
  4. Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Article
  16. Breast Cancer Response to Therapy: Can microRNAs Lead the Way?Journal of mammary gland biology and neoplasia · 2021
    Review
  17. Cytotoxic activities ofCytotechnology · 2021
    Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Nina PetrovicDepartment for Radiobiology and Molecular Genetics, Vinca Institute of Nuclear Sciences, University of Belgrade, Mike Alasa 12-14, 11000, Belgrade, Serbia. dragoninspiration@yahoo.com.
Sercan ErgunUlubey Vocational Higher School, Ordu University, 52850, Ordu, Turkey.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Standard cancer therapies for solid malignancies, such as chemotherapy and radiotherapy, are not target specific against cancer cells and are often not fully efficacious. Chemotherapy and radiotherapy may cause side effects, and the need to develop additional strategies for cancer treatment is urgent. MicroRNAs (miRNAs) are small non-coding RNAs with heterogeneous functions and have been described in almost every known cancer model. Besides their basic tumor-suppressive and oncogenic functions, they also have the potential to modulate chemotherapy and radiotherapy and to be manipulated with chemical compounds to make them chemically suitable for efficient delivery to cancer cells. It has been suggested that the level of expression of specific miRNAs could increase treatment efficacy by determining the stage of chemotherapy/radiotherapy sensitivity. Application of miRNAs alone or in combination with standard therapeutic strategies may significantly improve the success of cancer treatments in the future.

Indexed as

Molecular Targeted TherapyGene Transfer TechniquesHumansMicroRNAsNeoplasmsTreatment OutcomeMicroRNAs

Identifiers

PMID29335927

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.